The company continues to operate without meaningful revenue, reporting a quarterly operating loss of $8.2M in 2025Q4 as R&D expenditures climbed to $6.1M.
TuHURA Biosciences, Inc. (HURA) annual income statement — 12-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 23.47K | 0 | 0 | 55K | 60K | 60K | 32K | 10K | 16.35K | 24.53K | 16.68K | 10.29K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -23.47K | 0 | 0 | -55K | -60K | -60K | -32K | -10K | -16.35K | -24.53K | -16.68K | -10.29K | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | 100% | 8.33% | 0% | -87.5% | -220% | 38.83% | 33.35% | -47.02% | -62.16% | - | - |
| Operating Expenses | 31.17M | 31.8M | 17.65M | 8.4M | 14.74M | 22.62M | 21.54M | 8.13M | 8.38M | 11.15M | 8.3M | 6.2M | 4.72M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.64M | 7.58M | 3.87M | 5.73M | 5.42M | 7.45M | 9.72M | 4.5M | 4.72M | 4.02M | 3.3M | 2.84M | 2.17M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 22.88M | 20.53M | 13.34M | 2.66M | 9.31M | 15.17M | 11.81M | 3.63M | 3.66M | 7.13M | 5M | 3.36M | 2.56M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 1000K | 3.68M | 440.34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -31.2M | -31.8M | -17.65M | -8.45M | -14.8M | -22.68M | -21.57M | -8.14M | -8.4M | -11.17M | -8.32M | -6.21M | -4.72M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -80.15% | -108.84% | 42.88% | 34.77% | -5.15% | -164.88% | 3.03% | 24.84% | -34.3% | -33.9% | -31.52% | - |
| EBITDA | -31.1M | -31.72M | -17.53M | -8.4M | -14.74M | -22.62M | -21.54M | -8.13M | -8.38M | -11.15M | -8.3M | -6.2M | -4.35M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -18.51% | -80.94% | -108.82% | 43.02% | 34.86% | -5.02% | -164.81% | 2.96% | 24.82% | -34.27% | -33.86% | -42.76% | - |
| D&A (Non-Cash Add-back) | 95.41K | 71.27K | 116.71K | 55K | 60K | 60K | 32K | 10K | 16.35K | 24.53K | 16.68K | 10.29K | 378.97K |
| EBIT | -29.5M | -29.43M | -17.54M | -8.32M | -14.65M | -22.03M | -38.18M | -9.13M | -8.05M | -11.14M | -8.08M | -8.86M | -4.35M |
| Net Interest Income | -1.09M | -489.05K | -3.78M | 70.98K | 57.35K | -629.29K | -120K | 75K | 60.7K | 33.24K | 457 | 108 | -1.73K |
| Interest Income | 35.56K | 136.23K | 361.63K | 89.67K | 57.35K | 0 | 0 | 75K | 60.7K | 33.24K | 457 | 108 | 363 |
| Interest Expense | 1.12M | 625.28K | 4.14M | 18.69K | 0 | 629.29K | 120K | 0 | 0 | 0 | 0 | 0 | 2.09K |
| Other Income/Expense | 572.48K | 1.74M | -4.03M | 131K | 147K | 21K | -16.73M | -982K | 350.27K | 36.35K | 239.06K | -2.65M | 376.89K |
| Pretax Income | -30.62M | -30.06M | -21.68M | -8.32M | -14.65M | -22.66M | -38.3M | -9.13M | -8.05M | -11.14M | -8.08M | -8.86M | -4.35M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -30.63M | -30.06M | -21.68M | -8.32M | -14.65M | -22.66M | -38.3M | -9.13M | -8.05M | -11.14M | -8.08M | -8.86M | -4.35M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -10.33% | -38.64% | -160.6% | 43.2% | 35.36% | 40.83% | -319.66% | -13.39% | 27.74% | -37.82% | 8.83% | -103.89% | - |
| Net Income (Continuing) | -30.62M | -30.06M | -21.68M | -8.32M | -14.65M | -22.66M | -38.3M | -9.13M | -8.05M | -11.14M | -8.08M | -8.86M | -4.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.48 | -0.63 | -1.21 | -11.29 | -324.48 | -903.03 | -2805.84 | -1532.00 | -5524.99 | -9491.47 | -12950.00 | -14525.00 | -7700.00 |
| EPS Growth % | 84.57% | 47.93% | 89.28% | 96.52% | 64.07% | 67.82% | -83.15% | 72.27% | 41.79% | 26.71% | 10.84% | -88.64% | - |
| EPS (Basic) | - | -0.63 | -1.21 | -11.29 | -324.48 | -903.03 | -2805.84 | -1532.00 | -5524.99 | -9491.47 | -12950.00 | -14525.00 | -7700.00 |
| Diluted Shares Outstanding | 63.96M | 47.93M | 18.66M | 752.91K | 46.28K | 27.83K | 14.79K | 5.97K | 1.47K | 1.19K | 688 | 626 | 544 |
| Basic Shares Outstanding | 63.96M | 47.93M | 18.66M | 752.91K | 46.28K | 27.83K | 14.79K | 5.97K | 1.47K | 1.19K | 688 | 626 | 544 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying HURA stock.
For fiscal year 2025, TuHURA Biosciences, Inc. (HURA) reported total revenue of $0.0M.
TuHURA Biosciences, Inc. (HURA) reported a net loss of $30.1M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Imminent liquidity and dilution risk
Metrics are mathematically derived from official filings.
Escalating R&D Driven Burn Rate
As reported in recent financial statements, TuHURA Biosciences has seen its quarterly R&D expenditures climb to $6.1M by 2025Q4, reflecting the non-discretionary nature of its Phase 3 clinical trial commitments which continue to outpace the company's limited cash reserves and lack of operational revenue.
The company's cost structure is almost entirely comprised of clinical development expenses, which appear to be scaling as the IFx-2.0 program advances. This heavy reliance on external CROs and trial-related services suggests that management has little flexibility to curtail spending without jeopardizing the core registration-stage pipeline.
Operating Leverage Constrained by Development
Based on the company's reported figures, operating losses have widened significantly, reaching $8.2M in 2025Q4, which underscores the absence of operating leverage as the firm remains entirely focused on pre-revenue clinical execution rather than achieving any form of commercial or administrative efficiency at this stage.
The lack of revenue generation means that every dollar spent on SG&A and R&D flows directly to the bottom line as a loss. Investors should monitor whether the recent merger with Kintara Therapeutics provides any long-term administrative synergies, though current data suggests that overhead remains a persistent drag on liquidity.
Earnings Quality Obscured by Volatility
According to SEC filings, the company's net income is heavily impacted by non-operating items and merger-related accounting, with EPS figures showing extreme volatility that reflects the underlying instability of a pre-revenue biotech entity navigating complex corporate restructuring and significant share count fluctuations over the last ten quarters.
The reported net losses are likely exacerbated by non-cash charges related to warrant revaluations and merger-related accounting adjustments. These items make it difficult to assess the true operational burn rate, suggesting that analysts should focus on cash-based metrics rather than GAAP net income to gauge the company's actual runway.
Sustainability of Current Capital Structure
With a cash balance of only $3.6M as of the latest reporting, the company faces a critical funding gap that warrants further investigation into the likelihood of highly dilutive equity raises or restrictive licensing agreements required to sustain its ongoing Phase 3 clinical trial registration efforts.
The current cash position appears insufficient to support the high-cost environment of late-stage oncology trials, suggesting that the company is at a high risk of needing immediate capital. This creates a precarious situation where the market may be underestimating the potential for significant shareholder dilution in the near term.